Jump Financial, LLC Arcellx, Inc. Transaction History

Jump Financial, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$75.39 - $106.53 $328,625 - $464,364	4,359 New	4,359 $331,000
Q1 2024 May 13, 2024	SELL	$51.85 - $73.49 $304,515 - $431,606	-5,873 Reduced 38.68%	9,310 $647,000
Q4 2023 Oct 21, 2024	SELL	$31.75 - $57.99 $368,712 - $673,437	-11,613 Reduced 43.34%	15,183 $842,000
Q4 2023 Feb 07, 2024	BUY	$31.75 - $57.99 $482,060 - $880,462	15,183 New	15,183 $842,000
Q2 2023 Oct 21, 2024	SELL	$27.49 - $46.9 $92,228 - $157,349	-3,355 Reduced 11.13%	26,796 $847,000
Q2 2023 Aug 07, 2023	SELL	$27.49 - $46.9 $92,228 - $157,349	-3,355 Reduced 11.13%	26,796 $847,000
Q1 2023 Oct 21, 2024	BUY	$26.92 - $33.94 $811,664 - $1.02 Million	30,151 New	30,151 $928,000
Q1 2023 May 03, 2023	SELL	$26.92 - $33.94 $76,748 - $96,762	-2,851 Reduced 8.64%	30,151 $928,000
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $566,974 - $1.09 Million	33,002 New	33,002 $1.02 Million

214

48.8M

764K

296K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.58B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.